Table 3.
Reported sensitivities for homemade and commercial tularemia serological tests according to disease evolution.
| References | Method | Antibody types | Cutoff titers | Sensitivity at different time intervals of disease onset for (n) serum samples | ||
|---|---|---|---|---|---|---|
| 1st week (19) | 2nd week (13) | weeks 3–5 (28) | ||||
| (Carlsson et al., 1979) | ELISA | all | ≥500 relative titer | 15.8% | 50% | 96% |
| 0–5 days (11) | 6–10 days (12) | 11–20 days (30) | ||||
| (Koskela and Salminen, 1985) | TAT | mainly IgM | ≥10 | 7.1% | 65% | 97.8% |
| mainly IgM | ≥80 | 0% | 15% | 71.7% | ||
| CF-ELISA | all | ≥100 | 18.2% | 70% | 88% | |
| ELISA | IgM | ≥100 | 18.2% | 75% | 90% | |
| IgA | 9.1% | 58.3% | 90% | |||
| IgG | 36.4% | 91.7% | 90% | |||
| At least one | 36.4% | 91.7% | 96.7% | |||
| 1st week (NA) | 2nd week (NA) | |||||
| (Syrjälä et al., 1986) | MAT | mainly IgM | ≥10 | 65% | 89% | |
| mainly IgM | ≥80 | 3% | 52% | |||
| ELISA | IgM | ≥100 | 29% | 71% | ||
| IgA | ≥100 | 23% | 89% | |||
| IgG | ≥100 | 29% | 93% | |||
| At least one | ≥100 | 48% | 100% | |||
| 1st week (20) | 2nd week (86) | weeks 3–5 (76) | ||||
| (Kiliç et al., 2012) | Virapid ® ICT | All | ≥0.5 visual density | 20% | 67.4% | 96.1% |
| 1st week (7) | 2nd week (6) | weeks 3–4 (8) | ||||
| (Yanes et al., 2018) | MAT | all | ≥80 | 0% | 33.3% | 75% |
| IFA | IgM | ≥80 | 0% | 33.3% | 62.5% | |
| IgG | ≥160 | 0% | 0% | 87.5% | ||
| Serion ® ELISA | IgM | OD ≥ 0.45 | 14.3% | 66.7% | 100% | |
| OD ≥ 0.9 | 14.3% | 66.7% | 100% | |||
| IgG | OD ≥ 0.62 | 0% | 66.7% | 100% | ||
| OD ≥ 1.4 | 0% | 33.3% | 100% | |||
| Virapid ® ICT | all | + to +++ | 14.3% | 33.3% | 100% | |
TAT, tube agglutination test; MAT, microagglutination tests; LAT, latex agglutination test; IFA, immunofluorescence assay; ELISA, enzyme-linked immunosorbent assay; CF-ELISA, complement-fixing ELISA; ICT, immunochromatographic assay.